Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV‐1–Infected, Treatment‐Experienced Patients: AIDS Clinical Trials Group 5211
The Journal of Infectious Diseases2007Vol. 196(2), pp. 304–312
Citations Over TimeTop 1% of 2007 papers
Roy M. Gulick, Zhaohui Su, Charles Flexner, Michael D. Hughes, Paul R. Skolnik, Timothy Wilkin, Robert Gross, Amy Krambrink, Eoin Coakley, Wayne Greaves, Andrew Zolopa, Richard C. Reichman, Catherine Godfrey, Martin Hirsch, Daniel R. Kuritzkes
Abstract
In HIV-1-infected, treatment-experienced patients, vicriviroc demonstrated potent virologic suppression through 24 weeks. The relationship of vicriviroc to malignancy is uncertain. Further development of vicriviroc in treatment-experienced patients is warranted.
Related Papers
- → Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies(2021)45 cited
- → Safety and Tolerability of Gabapentin as Adjunctive Therapy in a Large, Multicenter Study(1999)81 cited
- → Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study(2022)4 cited
- Tolerability of topical antimicrobials in treatment of acne vulgaris.(2014)
- → TOPICAL MEDICINES IN THE TREATMENT OF ALLERGODERMATHOSIS(2017)